Status:
COMPLETED
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550 monotherapy (5 mg, 15 mg, and 30 mg twice daily \[BID\]) versus placebo administered over 6 weeks for the treatment...
Eligibility Criteria
Inclusion
- The subject has a history of inadequate response to at least 1, but no more than 4, of the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide, cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine)
Exclusion
- Current Therapy With Any DMARD Or Biologic
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT00147498
Start Date
January 1 2005
End Date
June 1 2006
Last Update
January 30 2013
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Upland, California, United States, 91786
2
Pfizer Investigational Site
Clearwater, Florida, United States, 33765
3
Pfizer Investigational Site
Miami, Florida, United States, 33173
4
Pfizer Investigational Site
New Port Richey, Florida, United States, 34652